Alkermes plc (NASDAQ:ALKS) Shares Bought by Fox Run Management L.L.C.

Fox Run Management L.L.C. boosted its position in shares of Alkermes plc (NASDAQ:ALKS) by 426.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 66,862 shares of the company’s stock after acquiring an additional 54,172 shares during the period. Alkermes comprises 0.3% of Fox Run Management L.L.C.’s investment portfolio, making the stock its 21st biggest holding. Fox Run Management L.L.C.’s holdings in Alkermes were worth $1,923,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Loomis Sayles & Co. L P boosted its holdings in shares of Alkermes by 365.5% in the 3rd quarter. Loomis Sayles & Co. L P now owns 1,882,936 shares of the company’s stock valued at $52,704,000 after buying an additional 1,478,422 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new position in shares of Alkermes in the 3rd quarter valued at $16,126,000. Raymond James Financial Inc. acquired a new position in shares of Alkermes in the 4th quarter valued at $12,293,000. C WorldWide Group Holding A S acquired a new position in shares of Alkermes in the 4th quarter valued at $7,190,000. Finally, Barclays PLC boosted its holdings in shares of Alkermes by 108.8% in the 3rd quarter. Barclays PLC now owns 423,931 shares of the company’s stock valued at $11,867,000 after buying an additional 220,893 shares in the last quarter. Institutional investors and hedge funds own 95.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ALKS shares. HC Wainwright restated a “neutral” rating and issued a $46.00 target price on shares of Alkermes in a report on Thursday, February 13th. UBS Group upgraded shares of Alkermes from a “sell” rating to a “neutral” rating and upped their price target for the company from $21.00 to $38.00 in a research report on Tuesday, March 4th. Royal Bank of Canada started coverage on shares of Alkermes in a research report on Thursday, March 13th. They issued a “sector perform” rating and a $40.00 price target for the company. The Goldman Sachs Group upped their price target on shares of Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Finally, StockNews.com upgraded shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $38.46.

Alkermes Stock Up 2.0 %

ALKS opened at $34.60 on Friday. The firm has a market capitalization of $5.63 billion, a P/E ratio of 15.94, a P/E/G ratio of 2.20 and a beta of 0.62. The firm’s 50 day moving average is $32.97 and its 200-day moving average is $30.04. Alkermes plc has a 52-week low of $22.90 and a 52-week high of $36.45.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. Equities analysts expect that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Insider Transactions at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 144,419 shares of Alkermes stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the transaction, the executive vice president now owns 57,875 shares of the company’s stock, valued at $2,056,298.75. The trade was a 71.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 4.89% of the company’s stock.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.